A Cambridge biotech, the first to go public in months, has hit the Nasdaq in a $185 million IPO in what industry watchers are hoping is an encouraging sign that the life sciences markets are beginning to stabilize.
A Cambridge biotech, the first to go public in months, has hit the Nasdaq in a $185 million IPO in what industry watchers are hoping is an encouraging sign that the life sciences markets are beginning to stabilize.
